Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology'
Fierce Pharma
DECEMBER 15, 2023
About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK. | About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.
Let's personalize your content